Literature DB >> 8123847

Differential effect of growth hormone and insulin-like growth factor-I, insulin-like growth factor-II, and insulin on Ig production and growth in human plasma cells.

H Kimata1, A Yoshida.   

Abstract

The effect of human growth hormone (GH) and insulin-like growth factor-I (IGF-I), IGF-II, and insulin on human plasma cell responses was studied. GH enhanced Ig production and thymidine uptake in the human plasma cell lines, IM-9 and AF-10. IGF-I, but not IGF-II or insulin, also enhanced Ig production and proliferation in them. However, enhancement by GH was not mediated by IGF-I, because enhancement was blocked by anti-GH antibody (Ab), but not by Ab to IGF-I or IGF-I receptor. Conversely, the enhancement by IGF-I was blocked by either Ab to IGF-I or IGF-I receptor, but not by anti-GH Ab. GH and IGF-I also enhanced production of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, and IgM and thymidine uptake in PCA-1+ plasma cells generated in vitro. Again, enhancement by GH was specifically blocked by anti-GH Ab, whereas enhancement by IGF-I was specifically blocked by either Ab to IGF-I or IGF-I receptor. These results indicate that GH and IGF-I may play important roles in plasma cell responses.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8123847

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Elevated cyclin E levels, inactive retinoblastoma protein, and suppression of the p27(KIP1) inhibitor characterize early development of promyeloid cells into macrophages.

Authors:  Q Liu; R W VanHoy; J H Zhou; R Dantzer; G G Freund; K W Kelley
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

2.  Secretory IgA in saliva can be a useful stress marker.

Authors:  S Tsujita; K Morimoto
Journal:  Environ Health Prev Med       Date:  1999-04       Impact factor: 3.674

Review 3.  Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Authors:  Terry J Smith
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 4.  Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.

Authors:  Terry J Smith; Laszlo Hegedüs; Raymond S Douglas
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2012-06       Impact factor: 4.690

5.  Assessment of immune function after short-term administration of recombinant human growth hormone in healthy young males.

Authors:  S B Ramos; E W Brenu; R Christy; B Gray; L McNaughton; L Tajouri; M Van Driel; S M Marshall-Gradisnik
Journal:  Eur J Appl Physiol       Date:  2010-12-08       Impact factor: 3.078

6.  Expression of lymphocyte-derived growth hormone (GH) and GH-releasing hormone receptors in aging rats.

Authors:  Douglas A Weigent
Journal:  Cell Immunol       Date:  2013-05-03       Impact factor: 4.868

7.  B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis.

Authors:  Raymond S Douglas; Vibharavi Naik; Catherine J Hwang; Nikoo F Afifiyan; Andrew G Gianoukakis; Daniel Sand; Shweta Kamat; Terry J Smith
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

8.  Divergent frequencies of IGF-I receptor-expressing blood lymphocytes in monozygotic twin pairs discordant for Graves' disease: evidence for a phenotypic signature ascribable to nongenetic factors.

Authors:  Raymond S Douglas; Thomas H Brix; Catherine J Hwang; Laszlo Hegedüs; Terry J Smith
Journal:  J Clin Endocrinol Metab       Date:  2009-02-24       Impact factor: 5.958

9.  Inhibitory Role of Growth Hormone in the Induction and Progression Phases of Collagen-Induced Arthritis.

Authors:  Ricardo Villares; Gabriel Criado; Yasmina Juarranz; Mercedes Lopez-Santalla; Eva M García-Cuesta; José M Rodríguez-Frade; Javier Leceta; Pilar Lucas; José Luis Pablos; Carlos Martínez-A; Marina I Garin; Rosa P Gomariz; Mario Mellado
Journal:  Front Immunol       Date:  2018-05-25       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.